Journal article
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
Abstract
BACKGROUND: Previous results from our phase 3 randomised trial showed that adding cetuximab to primary radiotherapy increased overall survival in patients with locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN) at 3 years. Here we report the 5-year survival data, and investigate the relation between cetuximab-induced rash and survival.
METHODS: Patients with LASCCHN of the oropharynx, hypopharynx, or larynx with …
Authors
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J
Journal
The Lancet Oncology, Vol. 11, No. 1, pp. 21–28
Publisher
Elsevier
Publication Date
January 2010
DOI
10.1016/s1470-2045(09)70311-0
ISSN
1470-2045
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCarcinoma, Squamous CellCetuximabChemotherapy, AdjuvantDose Fractionation, RadiationExanthemaFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm StagingProportional Hazards ModelsRisk AssessmentSeverity of Illness IndexSurvival AnalysisTime FactorsTreatment Outcome